Cost effectiveness of day 5 G-CSF (Lenograstim®) administration after PBSC transplantation: results of a SFGM-TC randomised trial-Reference-Cited by-同舟云学术

Cost effectiveness of day 5 G-CSF (Lenograstim®) administration after PBSC transplantation: results of a SFGM-TC randomised trial

Published:2005-07-11 Issue:6 Volume:36 Page:547-552
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Valteau-Couanet D,Faucher C,Aupérin A,Michon J,Milpied N,Boiron J M,Bourhis J H,Gisselbrecht C,Vernant J P,Pinna A,Bendahmane B,Delabarre F,Benhamou E

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1705097.pdf

Reference13 articles.

1. Hartmann O, Le Corroller AG, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600–607.

2. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

3. Bolwell B, Goormastic M, Dannley R et al. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day. Bone Marrow Transplant 1997; 19: 215–219.

4. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–2555.

5. Faucher C, Le Corroller AG, Chabannon C et al. Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Hematother 1996; 5: 663–670.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the Utility of Granulocyte Colony-Stimulating Factor Post-Autologous Hematopoietic Stem Cell Transplantation for Outpatient-Based Transplantations;Transplantation and Cellular Therapy;2023-11

2. The use of granulocyte colony stimulating factor after autologous hematopoietic stem cell transplantation;Bratislava Medical Journal;2019

3. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices;Biology of Blood and Marrow Transplantation;2018-02

4. G-CSF improves safety when you start the day after autologous transplant in multiple myeloma;Leukemia & Lymphoma;2017-05-16

5. Busulfan–melphalan in high-risk neuroblastoma: the 30-year experience of a single institution;Bone Marrow Transplantation;2016-04-04